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Abstract 
 
Glucocorticoids (GCs) exert their biological and therapeutical actions through the GC receptor 
(GR), a ligand-dependent transcription factor. Synthetic GC derivatives are widely prescribed 
for treating numerous cutaneous inflammatory and immune diseases due to their great efficacy. 
However, chronic treatment with GCs produces adverse side-effects including skin atrophy, 
delayed wound healing, and in certain cases, GC resistance. The mechanisms underlying the 
therapeutic actions of the GR in skin have been extensively studied; in contrast, the role of GR 
as a modulator of epidermal development and homeostasis has received less attention. The 
ubiquitous functional inactivation of GR results in defective epidermal formation although the 
underlying mechanisms have not been fully characterized. The use of transcriptomic approaches 
both in vitro and in vivo allowed the identification of genes that are regulated by GR in 
developing and adult skin. A main goal to understand the role of GR in skin biology is to 
identify primary transcriptional targets as well as the signaling pathways mediating GR action. 
Furthermore, it will be important to decipher the contribution of GR in the different cellular 
compartments of the skin, including keratinocytes of the interfollicular epidermis and hair 
follicles, and their respective stem cell progenitors. Additionally, recent findings indicating that 
the skin acts as a true peripheral endocrine organ implies greater complexity than originally 
thought. The local production of GCs and other steroid hormones should be considered as a 
modulator of skin function under homeostatic and diseased conditions. Finally, studying GR 
function in skin should take into account that the mineralocorticoid receptor may also mediate 
GC actions and/or regulate transcription either by itself or in combination with GR. Addressing 
these issues should help to elucidate the mechanisms by which GR contributes to establishment 
of a competent epidermal barrier and may also have implications in the context of 
dermatological treatments based on GC-analogs.  
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Introduction 
 
Glucocorticoids (GCs) are steroid hormones whose effects are mediated through the 
ubiquitously expressed intracellular GC receptor (GR), which belongs to the nuclear hormone 
receptor (NHR) superfamily.1,2 NHRs are ligand-dependent transcription factors that exert 
critical roles in skin function.3 In humans and mice, there is a single gene encoding for GR, 
called Nr3c1, composed by 9 exons.4,5 Nr3c1 undergoes both alternative splicing and alternative 
translational initiation, resulting in multiple GR protein isoforms. Alternative splicing generates 
multiple variants of which the most abundant and well studied are the GR and GR. GR is 
the predominant isoform and binds GCs whereas GR is expressed at much lower levels and is 
unable to bind endogenous or synthetic ligands.4-6 Increased ratios of GR/GR have been 
shown to correlate with resistance to GCs.7 Moreover, GR is known to negatively affects gene 
regulation by ligand bound GR.4-6 Alternative translation initation of GR has been shown to 
result in eight protein isoforms which exhibit differential expression in tissues, regulate the 
expression of unique gene subsets and have different sensitivity to GCs.4 In this review, we will 
mainly focus on the classical GRisoform, which we will refer to as GR. 
 
GR has a modular structure with three functional domains.1,2,5 The amino-terminal 
transactivation domain contains an activating function that is hormone-independent (AF-1) and 
is required for GR association with the basal transcription machinery. The DNA Binding 
Domain (DBD) is composed of two zinc fingers, the first of which is the proximal P-box and is 
responsible for GR binding to specific DNA sequences in target genes known as glucocorticoid-
response elements or GREs. The second zinc finger is the distal D-box and contains sequences 
important for receptor dimerization and nuclear translocation. The DBD is the most highly 
conserved domain throughout the steroid receptor family, which is particularly relevant for 
understanding the flexibility in the transcriptional regulation mediated by GR and other closely 
related nuclear receptors.1,2 The carboxy-terminal Ligand Binding Domain (LBD) binds to GCs 
and plays a critical role in the ligand-induced activation of GR. The LBD contains an additional 
activating function (AF-2), which is hormone-dependent and participates in interactions with 
other cofactors. A hinge region between the DBD and LBD confers structural flexibility 
allowing a single receptor dimer to interact with multiple GREs and it contains an additional 
nuclear localization signal. 
 
Upon GC binding, GR dissociates from cytoplasmic complexes, dimerizes and 
translocates to the nucleus, where it can modulate gene transcription in a cell type-specific 
manner.1,2,5 Typical GREs were defined by similarity to the consensus sequence 5´-
AGAACAnnnTGTTCT-3´. However, it has been demonstrated that binding of GR monomers to 
GRE half-sites is sufficient to mediate GR-dependent transcription in many genes.8-10 GR can 
also regulate gene expression through interference with other transcription factors, such as NF-
B, AP-1 or STATs, without direct binding to DNA.11-13 These protein–protein interactions can 
take place on regulatory sequences that do not contain GREs (tethering mechanism), as well as 
on DNA sequences that have both GREs and responsive elements of transcription factors that 
interact with GR (so-called composite elements). The mechanisms through which GR regulates 
gene expression are classically referred to as transactivation (TA; DNA-binding-dependent) and 
transrepression (TR; DNA-binding-independent). Classically, the TR function has been ascribed 
to the anti-inflammatory actions of GR whereas adverse side-effects have been linked to the TA 
function.11-13 TA and TR can be genetically dissected, as shown by the analysis of two mouse 
models: GR-/- mice, with total inactivation of GR14, 15, and GRdim/dim mice harboring a point 
mutation (A458T) in the D box DBD subdomain that renders GR defective in dimerization-
dependent transactivation16. GR-/- died perinatally due to the lack of alveolar surfactation 
whereas GRdim/dim mice survived.  
Accumulating evidence indicates that the binomial TA vs TR paradigm can no longer be 
sustained.17,18 First, it was reported that neither A458T nor other dimerization-defective mutants 
are globally TA-deficient, since the transcriptional potential of GR is dependent on the 
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particular context of given GRE.8-10 Finally, GRE-dependent transcription has been shown to be 
essential for the anti-inflammatory actions mediated by GR, for instance, through the induction 
of genes such as Mkp-1 and Ikba.17-19 
 
Post-translational modifications including phosphorylation, sumoylation and 
ubiquitination provide another level of control in the regulation of gene expression by the GR. 
Although it is known that these modifications alter GC signaling5, their exact 
pathophysiological consequences remain to be characterized. On the other hand, the so-called 
non-genomic actions of the receptor have been well studied and involve GR interference with 
the phosphatidylinositol 3-kinase (PI3K) signaling pathway and its effector kinase AKT, a key 
regulator of cell proliferation and survival. This interference takes place with rapid kinetics, is 
independent of transcription, and plays a crucial role in the therapeutic actions of GCs in several 
tissues, including the skin.20,21 
  
Given the prevalence of skin diseases and the great efficacy of using synthetic GC 
derivatives for treating these disorders, the study of GR has been of great interest. The 
knowledge regarding the mechanisms underlying GR therapeutical actions has been the topic of 
excellent reviews.7,11-13,17,18 However, the study of the role of GR as a modulator of the 
development of the epidermis and other stratified epithelia has received less attention. In this 
review, we mostly refer to the current knowledge regarding GR and skin homeostasis based on 
experimental mouse models. The generation and characterization of several genetically 
modified mice contributing to the understanding of GR function in developing and adult skin is 
summarized in Table 1. 
  
Epidermal development takes place during embryogenesis through a complex 
coordinated process by which a single-layered epithelium derived from the embryonic (E) 
ectoderm (E10.5) gives rise to a differentiated stratified epithelium.22-24 This process requires a 
correct balance between proliferation, differentiation and programmed cell death. The epidermis 
acts as a barrier preserving the organism from dehydration, infection, uncontrolled 
thermoregulation and environmental damage. In normal epidermis, only keratinocytes in the 
basal layer (BL) and hair follicles (HF) are able to proliferate.25 During differentiation basal 
keratinocytes cease to proliferate, lose adherence to the basement membrane and migrate to 
outer layers called spinous, granular and stratum corneum.22,23 Complex changes in gene 
expression culminate in the conversion of viable keratinocytes into the dead, flattened squames 
of the stratum corneum. Alterations in these processes during fetal development may lead to a 
disturbed epidermal barrier, which can cause skin disorders of keratinization and cornification 
ranging from mild epithelial defects to death.26 Even mild defects in skin development may have 
consequences in the adult age leading to increased susceptibility to skin infections and 
inflammation.24,26 There are multiple signaling pathways regulating skin development including, 
among others, nuclear factor kappa-B (NF-B), mitogen activated protein kinases (MAPKs), the 
epithelial-specific transcription factor p63 and Notch, which also regulate skin homeostasis in 
the adult animal.27 The epidermis maintains its capacity for self-renewal throughout life to 
ensure the reparation of the epithelial damage upon injury or infection. The homeostasis of this 
tissue is possible due to the epithelial stem cells, which are able to form the different cell 
lineages in the adult tissue and can be found in several compartments including the 
interfollicular epidermis, HF bulge and sebaceous glands.27 The mature HF consists of an outer 
root sheath contiguous with the basal layer of the epidermis, an inner root sheath serving as the 
channel from which the hair exits the skin surface, and the hair shaft itself.25,27 The HF along 
with the sebaceous glands and the arrector pili muscle form the pilosebaceous unit. Remarkably, 
this mini-organ undergoes cyclic transformations and regeneration during its entire life-time and 
is tightly controlled by hormone action, including GCs. During the process of HF 
morphogenesis a new hair forms and replaces the hair that degenerated and was released, 
through stages of rapid growth (anagen), apoptosis-driven regression (catagen), and quiescence 
(telogen).25 
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The skin as a peripheral endocrine organ 
 
GC synthesis and release is subjected to a tight neuro-endocrine control through the 
hypothalamic-pituitary-adrenal (HPA) axis.28 Under stress, the hypothalamus produces 
corticotropin-releasing hormone (CRH) that stimulates the release of adrenocorticotropic 
hormone (ACTH) from the pituitary gland. Subsequently, the adrenal cortex synthesizes GCs 
that are released into the bloodstream and distributed throughout the organism to maintain tissue 
homeostasis.28 
 
It is well established that the skin synthesizes vitamin D, retinoids, estrogens and 
progesterone, hormones that have a profound impact on skin pathophysiology.3 It was also 
shown that the skin is also able to synthesize cholesterol, the precursor of steroid hormones, as 
well as different components along the GC synthetic pathway such as CRH and ACTH.29,30 The 
observation that HFs can synthesize and secrete cortisol and modulate the production of other 
hormones by feedback mechanisms demonstrated that the skin itself acts as a peripheral 
endocrine organ.31 Very recently, it was reported that epidermal keratinocytes can synthesize de 
novo cortisol, both in vitro and in vivo, as well as the enzymes steroid 11 beta-hydroxylase 
(CYP11B1) and 11β-hydroxysteroid dehydrogenase 2 (11βHSD2).32 These enzymes catalyze 
the interconversion of active cortisol and inactive cortisone in humans (corticosterone and 
dehydrocorticosterone in rodents), thus controlling the biological availability of active 
hormone.29,30 
  
A main consequence of these findings is that GC action can be locally modified at the 
pre-receptor level through changes in the expression of these enzymes. Additionally, cortisol 
production can be triggered by other signals such as IL-1β, a key cytokine in epidermal injury, 
through CYP11B1 induction by keratinocytes.32 Conversely, the inhibition of cortisol synthesis 
during wound healing increases IL-1β production, thus representing a feed-back mechanism to 
modulate GC-mediated signaling. The existence of additional sources of steroid hormones 
represents a breakthrough for understanding GR action and, in a broader sense, nuclear hormone 
receptor function in skin. It also has important therapeutical consequences since local hormone 
production must be taken into consideration in the context of dermatological treatments based 
on GC-analogs.  
 
 
GR is required for epidermal barrier formation 
 
A major use of GCs in the clinic, when a premature birth is anticipated, is to accelerate alveolar 
surfactation and favor lung maturation, thus preventing the lethal respiratory syndrome.24 In this 
case, it is obvious that the benefit-risk ratio justifies this treatment. Although the impact of GCs 
in the skin maturation of premature infants is not well characterized, classical reports using 
murine models support a positive role of GCs in epidermal maturation. It was shown that GCs 
accelerated epidermal barrier formation when injected in utero to pregnant rats.33 Conversely, 
CRH-deficient newborn mice, which exhibited GC deficiency, had delayed maturation of the 
stratum corneum, which was fully rescued by GC supplementation.34 More recently, a study 
reported that the exposure of wild type (WT) early embryos (E15.5) to dexamethasone (Dex) in 
utero accelerated epidermal barrier formation by approximately 12h relative to controls.35 This 
resulted in significant changes in the transcriptional profile of Dex-treated relative to untreated 
skin only at this time-point, when the skin is still immature. Some of the genes identified as up-
regulated included the keratinocyte differentiation marker filaggrin as well as other genes 
mapping to the epidermal differentiation complex, a cluster encoding proteins of the outer 
epidermal layers. In contrast, when the embryo was exposed to the ligand at later developmental 
stages, only minor transcriptional changes were detected. Based on these data, the authors 
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postulated that GC actions were crucial for epidermal barrier acquisition in a critical 
developmental window (E15 to E15.5), prior to the observed accelerated barrier formation.35 
This developmental window fits with the endocrine anomalies described in GR-/- mice, featuring 
increased plasmatic ACTH and corticosterone levels that indicate that the HPA axis is active 
around E15.14 The timing of GC synthesis is in agreement with the expression pattern of GR in 
skin during mouse development; Nr3c1 mRNA peaks at the transition E14.5 to E16.5, 
correlating with the mRNA changes of the GR-regulated genes identified during skin 
development.36 This is in agreement with previous studies reporting GR mRNA up-regulation in 
fetal rat epidermis in late gestation.37  
 
Recently, the histopathological and molecular characterization of mice with general 
ablation of GR has shed light into the physiological role of this transcription factor during 
epidermal development.36,38 The epidermis of GR-/- E18.5 embryos exhibited an immature 
appearance with abnormal proliferating cells in the suprabasal layers and increased apoptosis 
throughout all epidermal layers. This, along with impaired keratinocyte differentiation resulted 
in incomplete epidermal stratification and a defective skin barrier.38 The number of anagenic 
growing HFs was unchanged in GR-/- E18.5 mice. However, the reduced expression of keratin 
K6, normally expressed at the inner root sheath but not interfollicular epidermis, is suggestive 
of altered HF differentiation. The skin phenotype of GR-/- embryos, together with other mouse 
models with GR gain- and loss-of-function in this tissue, is illustrated in Fig. 1. 
 
At the molecular level, the transcriptomic profile of GR-/- embryonic skin showed 
differential expression of genes belonging to the functional category of ectoderm/epidermis 
development.36 Some of the major constituents of the cornified envelope including several genes 
encoding for the small proline rich proteins (Sprrs) and corneodesmosin (Cdsn), as well as 
genes involved in epidermal terminal differentiation (Ptgs1 and Bcl6) were strongly down-
regulated. Also, Krt77 and the epithelial-specific transcription factor Elf5, two genes expressed 
at relatively high levels during earlier stages of epidermal development were highly up-
regulated in the GR-deficient skin. These gene expression changes with aberrant expression of 
epidermal differentiation markers has been reported in several mouse models with impaired 
barrier formation.22 The differential expression profile in GR-/- mouse skin also included genes 
involved in apoptosis and lipid metabolism, two processes with a major role in epidermal barrier 
formation.36 
 
Previous findings reported the changes in gene expression after Dex treatment in 
cultured human keratinocytes39. In this work, Stojadinovic and coworkers showed that Dex 
treatment up-regulated genes involved in stratum corneum formation, such as transglutaminase 
1, filaggrin and Cdsn. Also, GCs inhibited involucrin expression specifically in the lower 
suprabasal layers as well as that of Jagged and AP2-, two genes that promote early keratinocyte 
differentiation. The authors suggested that GCs may have a dual effect on epidermal 
differentiation by promoting late differentiation while simultaneously inhibiting the early 
stages.39 Besides, they also demonstrated that GCs induce the expression of anti-apoptotic genes 
and repress pro-apoptotic genes.  
 
In vitro studies using cultured mouse primary keratinocytes (MPKs) isolated from GR-/- 
mice demonstrated that keratinocyte proliferation and apoptosis was regulated in a cell-
autonomous manner.38 However, although epidermal differentiation was severely impaired in 
vivo, cultured GR-/- MPKs were able to differentiate in the presence of high calcium, a classical 
model of in vitro keratinocyte differentiation.38 Besides, the gene expression changes detected in 
cultured keratinocytes upon Dex treatment showed some discrepancies relative to GR-/- 
MPKs.36,39 These differences may be explained by culture conditions as well as by the Dex dose 
and kinetics.35,36,39  Although the use of cultured cells provides relevant information, it seems 
reasonable to assume that the in vitro studies using MPKs do not fully recapitulate skin 
physiology. The generation of a mouse model with keratinocyte-restricted constitutive GR 
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inactivation will allow for study of the epithelial contribution of GR in skin development and 
disease. 
 
It has been suggested that GR acts in conjunction with the transcriptional regulator 
Krüppel-like factor 4 (KLF4) to coordinately regulate epidermal barrier formation.35 This study 
used E15.5 WT mice as well as embryos with either KLF4 inactivation (KLF4-/-) or 
keratinocyte-specific KLF4 overexpression (K5-KLF4 mice) to analyze the coordinated actions 
of GCs and KLF4. The comparison of the skin transcriptomic profile of these mouse models 
showed significant overlap of genes regulated by GR and KLF4. Although the authors reported 
that Klf4 was not induced upon Dex treatment in vivo, it was reported to be induced by Dex in 
human cultured keratinocytes; this controversy is likely due to the different experimental 
models.35,39   
 
Some issues need to be taken into account for interpretation of the gene expression data 
obtained in GR-/- embryonic skin. First, the skin phenotype of the total GR knock-out may be 
due to the lack of GR in other cell types besides keratinocytes. Second, GR-/- mice have 
increased circulating hormone levels that might contribute to the observed skin phenotype. This 
raises a very interesting issue, the possibility that the elevated levels of GCs in GR-/- embryos 
may signal through the closely related mineralocorticoid receptor (MR) since it also binds GCs 
with high affinity. This is biologically relevant as both receptors recognize the same GREs and 
GR can heterodimerize with MR. These issues open the question of whether the lack of GR 
along with increased GC levels could result in increased MR signaling; should this be the case, 
MR would contribute to the observed GR-/- skin phenotype (see below). 
 
 
Transcriptional and non-transcriptional functions of GR in skin development 
 
The histopathological analysis of GRdim/dim mouse skin revealed no differences relative to WT 
mice in either epidermal or HF formation.38 In addition, no changes in the expression and/or 
localization of several markers of epidermal differentiation were detected. This led to the 
postulation that the DNA-binding-independent actions of GR were sufficient to mediate 
epidermal and HF development during embryogenesis. However, since most genes in their 
natural context contain non-conventional GRE sites and/or composite elements, it is also 
possible that these genes are transcriptionally regulated in the GRdim/dim mice through direct 
binding of GR monomers to DNA.10   
 
Recent data have demonstrated that most GR binding sites (GBS) are distributed evenly 
through the genome, which explains the difficulty of identifying GR transcriptional targets by 
conventional approaches searching for consensus GBS sequences in proximal promoters.10,40,41  
The low overlap of GC-regulated genes among different cell types found by transcriptomic 
approaches supports that the contribution of cell-type specific transcription factors and 
coregulators is crucial to modulate GR-mediated transcription. The identification of primary 
GR-target genes in skin has been so far limited to conventional chromatin immunoprecipitation 
(ChIP) assays. This approach allowed identifying FK506-binding protein 51 (Fkbp51) and 
defensin beta 1 (Defb1) as primary GR-target genes in keratinocytes.36 However, for those genes 
that did not show GR bound to candidate regulatory sequences, such as Krt77 and Elf5, it can 
not be ruled out that GR binds to other genomic sequences. Future advances rely on high 
throughput techniques of ChIP combined with either promoter array tiling (ChIP-chip) or 
parallel whole-genome sequencing (ChIP-seq)42, allowing the mapping of GBSs, which will 
eventually allow the identification of GR primary target genes in skin.  
 
Further evidence supports the idea that the mechanisms by which GR regulates 
epidermal formation are mediated through its DNA-binding-independent actions. On one hand, 
the activity of the MAPK ERK was constitutively increased in GR-/- skin and MPKs relative to 
WT, suggesting that GR modulates skin homeostasis, at least partially, by antagonizing ERK 
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function.38 Supporting this, a selective ERK pharmacological inhibitor partially reversed the 
increased apoptosis of GR-/- MPKs. GR-/- skin showed alterations in the activity of caspase-14, a 
non-apoptotic epidermal-specific caspase that normally induces the formation of mature 
filaggrin and its degradation into free amino acids, thus providing a competent stratum 
corneum.43 The lack of GR caused deficient processing of caspase-14 into active caspase-14 
although no changes were detected in its transcript levels.38 
 
 
GR regulates epithelial morphogenesis 
 
The control of a precise spatiotemporal expression pattern of GR and its ligand is crucial for 
normal embryo development.44 Under normal circumstances, the embryo is protected from 
excess GCs by the activity of 11ßHSD2 which is present at high levels in the placenta. If the 
mechanisms of control fail, the consequences are deleterious, as evidenced by the teratogenic 
effects of GCs, which include reduced birth weight, increased HPA axis reactivity, 
hyperglycemia and hypertension.44 Although the precise mechanisms underlying these GC 
effects are not fully understood, they correlate with altered expression levels and activity of GR 
in the affected tissues. Moreover, excess GCs can also elicit epigenetic changes in the GR-target 
gene promoters.45  
 
Consistent with the teratogenicity of high levels of GCs, our previous work 
demonstrated that GR overexpression in epithelial basal cells by means of the keratinocyte-
specific K5 promoter (K5-GR mice) affected all ectoderm-derived epithelia.46-48 K5 regulatory 
sequences drive transgene expression following a well defined expression pattern in the basal 
cells of stratified epithelia starting around E13.549. K5-GR mice exhibited abnormal 
morphogenesis of the epidermis, hair, teeth, and exocrine glands.46,48 In fact, the phenotype of 
these mice recapitulates the triad of clinical signs that define the human syndrome hypohidrotic 
ectodermal dysplasia (HED).50 The severity of the epithelial phenotypes correlated with 
transgene expression levels ranging from epidermal hypoplasia and underdeveloped, dysplastic 
hair follicles to a complete absence of all epidermal layers (Fig. 1). Other epidermal appendages 
such as vibrissae and eyebrows also appeared underdeveloped.46 The fact that higher GR dosage 
elicits more severe phenotypes underlines the requirement of a balanced GR-mediated signaling 
during epithelial morphogenesis. A common feature of HED patients also found in several 
mouse models for this disease is defective IB kinase (IKK)/NF-B signaling.50 K5-GR mice 
showed decreased IKK and IKK expression and reduced NF-B activity in tooth epithelial 
cells.48 This is in agreement with the known antagonism between GR and the IKK/NF-B 
pathway in many cell types including keratinocytes.11,21 
 
The developing skin of K5-GR mice showed a reduced proliferation rate of the 
keratinocytes (approximately 30%) from E16.5 to the postnatal (P) age.46 The growth inhibitory 
effect of GR is in agreement with the known anti-mitotic effects of topically applied GCs in 
skin in vivo51 as well as in keratinocyte cell lines.52 It is indeed remarkable that the 
overexpression of MR under the K5 promoter (K5-MR mice)53 causes a phenotype highly 
similar to that of K5-GR mice. K5-MR mice featured atrophic skin, a reduced number of hair 
follicles, increased keratinocyte apoptosis and premature epidermal barrier formation.53 These 
alterations led to perinatal death, as occurred with the highest expressing K5-GR transgenic line. 
The epidermal maturation of K5-GR embryos has not been tested by permeability assays, 
however, immunostaining showed increased expression of the keratinocyte differentiation 
marker loricrin (unpublished results). Moreover, the enzyme 3-hydroxy-3-methylglutaryl- CoA 
synthase (Hgmcs2), specifically involved in steroid and lipid biosynthesis, was up-regulated in 
these mice, suggesting an accelerated epidermal barrier formation.54 Hmgcs2 is a transcriptional 
target of other NHRs.55 It is not clear whether MR overexpression accelerates epidermal 
maturation by inducing keratinocyte differentiation and/or by changing the levels and/or 
composition of epidermal lipids.  
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The phenotypical coincidences between K5-GR and K5-MR transgenic mouse models 
include an eyelid-open-at birth (EOB) phenotype but exclude alterations in vibrissae, teeth, or 
palate46,53. Unexpectedly, GR-/- embryos also showed a EOB phenotype.56 Eyelid epithelial 
defects were due, at least in part, to the lack of antagonism between GR and epidermal growth 
factor receptor (EGFR) signaling, causing sustained activation of ERK and the upregulation of 
K6 in E18.5 embryos. In vivo K6 induction in the epithelial cells of GR-/- embryos is likely 
mediated through AP-1 sites in its promoter.57 Conversely, GR inhibited keratinocyte migration 
in vitro by interfering with EGFR-mediated signaling in the eyelid epithelium.56 Although the 
mechanisms mediating the EOB phenotype in K5-MR have not been addressed, it could be 
speculated that MR and GR use similar mechanisms to regulate eyelid epithelial development. 
Altogether, and as it has been recently suggested, it seems relevant to further study the role of 
MR in the cutaneous biology.58 
 
The examination of a mouse model expressing the GR P493R/A494S (GR-TR) mutant 
under the control of K5 promoter (K5-GR-TR) has provided important results.59 GR-TR is a 
transactivation-defective mutant that retains the transrepression properties. The comparison of 
the effects of GR vs GR-TR in the epidermis and other stratified epithelia in vivo is feasible 
since both transgenes use the same regulatory sequences and are expressed at similar protein 
levels. Contrary to K5-GR mice, the skin architecture of K5-GR-TR mice in the perinatal period 
showed no significant changes (Fig. 1). Furthermore, the levels and pattern of expression of 
markers of proliferation or differentiation of the epidermis or HFs at this stage were also 
unchanged.59 However, K5-GR-TR embryos exhibited an EOB phenotype almost identical to 
K5-GR and K5-MR mice.47,53,59 This indicates that the mechanisms by which GR regulates 
epithelial development are tissue-specific. Moreover, while the overexpression of GR-TR did 
not disturb epidermal development, it caused severe alterations in the adult epidermis and HFs. 
These temporal-specific actions have also been described for other nuclear hormone receptors 
such as the retinoid X receptor  and the vitamin D receptor, which also affected specifically 
HF function in the adult age.3 
 
 
GR mechanisms modulating adult skin homeostasis 
 
The adverse reactions that accompany GC therapy upon prolonged treatments have been well 
characterized and include skin atrophy, delayed wound healing, and more rarely GC 
resistance.51 In addition, short-term topical and systemic GC treatment to adult mouse skin 
disturbed epidermal barrier competence, an effect also induced by psychological stress, likely 
due to the increased production of endogenous GCs.60,61 Skin atrophy is one of the most 
common GC-associated side-effects and consists in the reduction in skin thickness and elasticity 
as well as increased fragility. Together, these features result in impaired skin barrier function. In 
the adult age, K5-GR and K5-GR-TR mice showed a similar skin phenotype featuring 
epidermal thinning and a significant reduction in the number of hair follicles (25% and 50%, 
respectively)48,59 (Fig. 1). These effects reproduce the skin atrophy and occasional alopecia 
observed after prolonged treatments with GC analogs in human patients.51  
 
GCs are known inhibitors of keratin gene expression including K5/K14 and K6/K16, 
which are markers of keratinocyte proliferation under physiological (K5/K14) and pathological 
(K6/K16) circumstances.57 This inhibition mainly occurs by two independent mechanisms, both 
mediated through its transrepression function. One of these mechanisms requires the binding of 
GR monomers to GREs at the keratin promoters whereas the other involves protein-protein 
interactions between GR and AP-1, suppressing AP-1-mediated induction.62 In both cases, GR 
monomers are sufficient to mediate these actions. GR/AP-1 cross-talk is very relevant in skin 
since AP-1 is crucial for many processes in skin physiopathology including epithelial 
development, skin inflammation and cancer.63 This antagonism has been demonstrated in vivo in 
several transgenic mouse models. The adult skin of K5-GR and K5-GR-TR mice showed 
reduced expression of K5.46,59 Furthermore, the expression of K6, a marker of hyperproliferative 
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skin diseases, which is induced upon treatment with the phorbol ester PMA, was strongly and 
similarly repressed in mice overexpressing either GR or GR-TR.59 In GRdim/dim adult mouse skin, 
the PMA-induced expression of two AP-1-target genes encoding for matrix metalloproteinases, 
Mmp-3 and Mmp-13, was efficiently inhibited.64 However, the scenario is rather complex since, 
as reported for other cell types, the formation of several AP-1 hetero- and homo-dimeric 
complexes may result in differential regulation of AP-1-target genes.63 This might explain the 
observed up-regulation of the AP-1 target gene Mmp-11 gene, which also contains AP-1 
binding sites in its promoter, in K5-GR mouse skin.54 
 
Based on the possibility to dissociate the transactivation and transrepression functions 
of GR, several non-steroidal selective GR agonists or SEGRAs have been developed.51 The 
parameters used to determine whether SEGRAs have a better therapeutical index relative to 
classical GC treatments include skin atrophy, reduced inflammation and suppression of the HPA 
axis activity. Usually, the profile of SEGRAs is tested by using in vivo65 and, more recently, in 
vitro66 models. Some of these novel compounds offer promising approaches for the treatment of 
skin diseases.51 The experimental data using GR mouse models suggest further complexity 
regarding the dissociation of the GR functions; however, this does not necessarily recapitulate 
the clinical situation. A comparative study of the responses of K5-GR and K5-GR-TR mice to 
acute and chronic PMA revealed that GR-TR can efficiently repress IL-1and Mmp-3 
transcription (to a similar extent than GR) whereas GR-TR only weakly repressed IL-6 and 
TNF- transcripts.59 These data illustrate that the GR-TR mediated repression occurs in a gene-
specific manner. Moreover, it reinforces the idea that transactivation by the GR is indeed 
relevant for the GC anti-inflammatory actions. 
 
The use of of gain- and loss-of function approaches should contribute to a better 
understanding of the functional role of GR. Until recently, this was not feasible given the 
perinatal lethality of the GR-/- mice.14,15 The generation of a conditional knock-out mouse model 
with keratinocyte-restricted GR inactivation inducible in adult animals (K14-cre-
ERT2//GRloxP/loxP mice) has demonstrated the epithelial contribution of GR in adult skin 
homeostasis.36 K14-cre-ERT2//GRloxP/loxP mice featured thickened skin with increased 
keratinocyte proliferation and inflammation, as well as impaired epidermal differentiation, 
demonstrating that GR function in keratinocytes is required for proper skin homeostasis (Fig. 1). 
Many of the genes identified as GR-regulated during skin development were similarly 
controlled in the adult tissue, including Cdsn, Sprr2d, Defb1 and Fkbp51. However, other genes 
such as Krt77 and Elf5 were regulated by GR exclusively during embryonic development. 
Altogether, these data indicate that GR regulates common and differential gene subsets in 
embryonic and adult skin. It will be important to study the role of Fkbp51and Defb1 genes, 
which were also identified as primary GR transcriptional targets.36 Fkbp51 expression has been 
described in adult follicular stem cells67 as well as in epidermal keratinocytes.36 The 
antimicrobial peptide defensin 1 (Defb1) is related to the innate immune response and 
epithelial defense. Importantly, the decreased Defb1 mRNA expression and reduced terminal 
differentiation observed in the embryonic GR-/- and the adult K14-cre-ERT2// GRloxP/loxP skin 
suggest a role for this gene in keratinocyte differentiation in vivo.36  
 
The prolonged use of GCs may result in the development of GC-resistance in several 
allergic and inflammatory diseases7 although this phenomenon is rare in dermatology. In skin, 
the GC-induced resistance can produce a paradoxical effect by which GCs lead to 
hyperproliferation instead of growth inhibition. It was postulated that GC-induced 
desensitization could be due to differential responses in distinct keratinocyte subpopulations.68 
Chebotaev and coworkers reported that topical chronic GC treatment of mouse adult skin 
significantly decreased GR expression in interfollicular epidermal keratinocytes but not in the 
hair follicle bulge keratinocytes. These results suggest that the increased sensitivity of bulge 
keratinocytes to the antiproliferative effect of GCs is due to the contribution of the epidermal 
stem cells located in this compartment.68 The examination of additional stem cell populations 
located in the IFE and sebaceous glands would add to this conclusion.27 
 11
 
Despite its relevance, the mechanisms underlying GR function in HFs are not well 
characterized. The overexpression of GR and GR-TR in basal keratinocytes resulted in a 
reduced number of HFs as well as impairment in HF proliferation and differentiation.46,54,59 The 
atrophic HFs were often accompanied by hyperplasic sebaceous glands, a common response 
secondary to alopecia. Besides, K5-MR adult mice generated by conditional postnatal 
expression of MR to overcome the perinatal lethality also showed a severe skin phenotype. The 
skin of these mice featured dysplasic HFs leading to cysts and progressive alopecia.53 The 
formation of cysts usually occurs when the HFs are irreversibly damaged, as reported in other 
mouse models with NHR inactivation such as retinoid  X receptor  conditional epidermal 
knock-out and vitamin D receptor-deficient mice; both of these mouse models also have 
progressive alopecia.3 
 
At the molecular level, the analysis of the gene expression profile of K5-GR adult skin 
supported a role for GR in HF differentiation.54 Among the identified genes, there was a large 
subset of hair keratin intermediate filament (krt) and hair keratin-associated protein (krtap) 
genes, as well as several hox genes. This is clinically relevant since dysregulation of krt, krtaps 
and hox genes can cause hair disorders.69 KRTAPs are essential to form a rigid and resistant hair 
shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of 
hair keratins. Hox genes, besides playing a major role in HF development and cycling, have 
been involved in transcriptional regulation of krtaps.70  
 
 
Conclusions and perspectives 
 
Several transcriptomic analyses have reported that in keratinocytes, GR regulates the expression 
of a variety of genes, including those involved in apoptosis, cellular adhesion, lipid metabolism 
and formation of the stratum corneum.  Based on these data, it is particularly relevant to perform 
functional studies that help to dissect the exact mechanisms by which GR regulates keratinocyte 
terminal differentiation and epidermal barrier formation. Alterations in these processes during 
embryogenesis can result in increased susceptibility of adult individuals to inflammatory skin 
diseases such as psoriasis and atopic dermatitis. Therefore, studying the mechanisms of GR 
function during development and identifying GR primary targets will be useful for designing 
therapies based on GC analogues. A major question that remains unanswered is whether the 
epithelial contribution of GR is required for normal skin development as well as to mediate the 
therapeutical actions of GCs in different skin diseases. In order to answer these questions, it is 
necessary to study a mouse model with constitutive GR inactivation restricted to keratinocytes.  
 
Recently, several additional GR isoforms have been identified, although no information 
of their expression and activity has been reported in the skin. The tissue-specific expression 
patterns and post-translational regulatory mechanisms for these isoforms add further complexity 
to the understanding of GR signaling. GR has been postulated as a dominant negative form of 
GR-dependent transcription that could be responsible for GC resistance in inflammatory 
diseases. Considering the wide use of the GCs in clinical practice, the variable outcome of GC 
treatment among patients, and the phenomenon of GC resistance, it is a main goal to determine 
the underlying causes for the differential GC responses in order to design and adjust the GC-
based treatments to achieve best efficacy with minimal adverse effects.  
 
Additionally, given the interactions among different nuclear hormone receptors and the 
prescription of combined hormone analogs for treating skin diseases, future work should be 
aimed at deciphering the complex interactions between different hormone signaling pathways. 
Supported by recent findings, it seems particularly relevant to analyze a possible cross-talk 
between GR and MR in keratinocytes, which may have consequences in GC-based therapies. 
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